Enbrel recombinant p75 TNF receptor linked to human IgG1 Fc: Open-label safety study; BLA filed

IMNX presented 18-month data from its ongoing open-label safety study of patients who continued Enbrel treatment after the conclusion of previous trials (see BioCentury, May 4). A total of 72 patients have completed 18 months of treatment with 25 mg Enbrel twice weekly. Both safety and treatment benefit were consistent with the 15 month results.

The data were presented at the Pan American Congress of Rheumatology meeting in Montreal. ...